Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_center">Gene</td><td class="align_center">Primer sequence (5<span class="nowrap"><svg height="11.4859pt" id="M4" style="vertical-align:-0.04979992pt" version="1.1" viewbox="-0.0498162 -11.4361 3.89517 11.4859" width="3.89517pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M310 541L304 571C290 586 211 619 185 610L80 76L131 52L310 541Z"></path></g></svg>-</span>3<span class="nowrap"><svg height="11.4859pt" id="M5" style="vertical-align:-0.04979992pt" version="1.1" viewbox="-0.0498162 -11.4361 3.89517 11.4859" width="3.89517pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M310 541L304 571C290 586 211 619 185 610L80 76L131 52L310 541Z"></path></g></svg>)</span></td><td class="align_left">Amplicon size (bp)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_center"><i>SphK1</i></td><td class="align_center">F: CTTCCTTGAACCATTATGCTG<br/>R: GCCGATACTTCTCACTCTC</td><td class="align_left">204</td></tr><tr><td class="align_center"><i>Hprt</i></td><td class="align_center">F: AAGCTTGCTGGTGAAAAGGA<br/>R: TTGCGCTCATCTTAGGCTTT</td><td class="align_left">198</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Hypoxanthine–guanine phosphoribosyltransferase (hprt), housekeeping, and target gene primer sequence. SphK: sphingosine kinase.</div>

Cardiovascular Therapeutics

tab1

Table 1

Table 1: Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 

Table 1 | Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 